

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12Q 1/68, C07H 21/00, B01J 19/00</b>		A1	(11) International Publication Number: <b>WO 95/21265</b>
			(43) International Publication Date: 10 August 1995 (10.08.95)
(21) International Application Number: PCT/GB95/00209		<b>(81) Designated States:</b> JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(22) International Filing Date: 1 February 1995 (01.02.95)			
(30) Priority Data: 9401833.0 1 February 1994 (01.02.94) GB			
(71) Applicant (for all designated States except US): ISIS INNOVATION LIMITED [GB/GB]; 2 South Parks Road, Oxford OX1 3UB (GB).			
(72) Inventors; and (75) Inventors/Applicants (for US only): SOUTHERN, Edwin, Mellor [GB/GB]; 30 Staverton Road, Oxford OX2 6XJ (GB). MIR, Kalim, Ullah [GB/GB]; 2 Grange Drive, Bradford BD15 7Z (GB). CASE-GREEN, Stephen, Charles [GB/GB]; Flat 2, Sylvia House, 32A Union Street, Oxford OX4 1JP (GB).			
(74) Agent: PENNANT, Pyers; Stevens, Hewlett & Perkins, 1 Serjeants' Inn, Fleet Street, London EC4Y 1LL (GB).			
<b>(54) Title: METHODS FOR DISCOVERING LIGANDS</b>			
<b>(57) Abstract</b>  A method of identifying one or a combination of ligands, e.g. oligonucleotides or analogues, that interact specifically with a target, e.g. a DNA or an RNA molecule having a secondary or tertiary structure. One ligand may be pre-reacted to open up the target for interaction with other ligands forming an array on a solid surface.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				



2/15

Fig.2a.

Analysis on scanning arrays


tRNA<sup>phe</sup>


Fig.2b.

HIV TAR



3/15

Fig.3.




Hybridisation of tRNA<sup>phe</sup>  
to an array of the type  $N_3X_2N_3$

4/15

Fig.4.

tRNA with cooperative antisense interactions



5/15





Fig. 5.


6/15

Fig.6.





7/15




**Fig. 7a.**

# HIV RRE ELEMENT

8/15


Fig.7b.



SUBSTITUTE SHEET (RULE 26)

9/15

Fig.7c.



10/15

Fig.8a.






Fig.8b.



11/15

Fig.8c.



12/15

Fig.9a.





Fig.9b.



13/15

Fig.10a





Fig.10b




14/15

Fig.11a.




Fig.11b.





15/15

Fig.11c.



agccagatctgagcctgggagctctctggc

